Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis

Efficacy and Safety of High-Density Lipoprotein/Apolipoprotein A1 Replacement Therapy in Humans and Mice With Atherosclerosis: A Systematic Review and Meta-Analysis

Background: Although elevation of HDL-C levels by pharmaceutical drugs have no benefit of cardiovascular endpoint, the effect of high-density lipoprotein/apolipoprotein A1 (HDL/apoA-1) replacement therapy on atherosclerosis is controversial. The current meta-analysis analyzed the effects of HDL/apoA...

Full description

Bibliographic Details
Main Authors:	Ayiguli Abudukeremu, Canxia Huang, Hongwei Li, Runlu Sun, Xiao Liu, Xiaoying Wu, Xiangkun Xie, Jingjing Huang, Jie Zhang, Jinlan Bao, Yuling Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-08-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	lipoproteins HDL apolipoprotein A-I mimetic atherosclerosis
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2021.700233/full

Similar Items

Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice
by: Andrea Rivas-Urbina, et al.
Published: (2020-05-01)

A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids
by: Mohamad Navab, et al.
Published: (2009-08-01)

Apolipoprotein Mimetic Peptides: A New Approach for the Treatment of Asthma
by: Xianglan eYao, et al.
Published: (2012-03-01)

Influence of route of administration and lipidation of apolipoprotein A-I peptide on pharmacokinetics and cholesterol mobilization
by: Jie Tang, et al.
Published: (2017-01-01)

Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits
by: Brian J. Van Lenten, et al.
Published: (2007-11-01)

Association of human apolipoprotein E with lipoproteins secreted by transfected McA RH7777 cells
by: Catherine A. Reardon, et al.
Published: (1998-07-01)

Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research
by: Karin Kornmueller, et al.
Published: (2019-08-01)

D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal inflammation in LDL receptor-null mice fed a Western diet
by: Georgette M. Buga, et al.
Published: (2008-01-01)

Cholesterol–sphingomyelin interaction in membrane and apolipoprotein-mediated cellular cholesterol efflux
by: Jin-ichi Ito, et al.
Published: (2000-06-01)

Characteristics of lipid metabolism including serum apolipoprotein M levels in patients with primary nephrotic syndrome
by: Lagu He, et al.
Published: (2017-09-01)

High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease
by: Elizabeth M. Gordon, et al.
Published: (2016-09-01)

Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome is associated with HDL functions in diabetic kidney disease without dialysis
by: Monique F. M. Santana, et al.
Published: (2020-09-01)

Regulation of human apolipoprotein A-I gene expression by equine estrogens
by: Xia Zhang, et al.
Published: (2001-11-01)

Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review
by: C. Roger White, et al.
Published: (2014-10-01)

Volumetric determination of apolipoprotein stoichiometry of circulating HDL subspecies1[S]
by: Jere P. Segrest, et al.
Published: (2013-10-01)

Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis
by: Eftaxia-Konstantina Valanti, et al.
Published: (2018-10-01)

Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases
by: Anna Wolska, et al.
Published: (2021-03-01)

Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer
by: Konstantina Georgila, et al.
Published: (2019-08-01)

Apolipoprotein A-I promotes cholesterol release and apolipoprotein E recruitment from THP-1 macrophage-like foam cells
by: John K. Bielicki, et al.
Published: (1999-01-01)

Apolipoprotein E3-mediated cellular uptake of reconstituted high-density lipoprotein bearing core 3, 10, or 17 nm hydrophobic gold nanoparticles
by: Chuang ST, et al.
Published: (2017-11-01)

Evidence for differential effects of apoE3 and apoE4 on HDL metabolism
by: Paul C.R. Hopkins, et al.
Published: (2002-11-01)

Apolipoprotein and lipid abnormalities in chronic liver failure
by: A.C. Spósito, et al.
Published: (1997-11-01)

Apolipoprotein E particle size is increased in Alzheimer's disease
by: Thomas J. Nelson, et al.
Published: (2019-12-01)

Advances in HDL: Much More than Lipid Transporters
by: Soumaya Ben-Aicha, et al.
Published: (2020-01-01)

Anti-tumorigenic and Platinum-Sensitizing Effects of Apolipoprotein A1 and Apolipoprotein A1 Mimetic Peptides in Ovarian Cancer
by: Aline T. Marinho, et al.
Published: (2019-01-01)

Apolipoprotein A-I: structure–function relationships
by: Philippe G. Frank, et al.
Published: (2000-06-01)

Preparative free-solution isotachophoresis for separation of human plasma lipoproteins: apolipoprotein and lipid composition of HDL subfractions
by: Alfred Böttcher, et al.
Published: (2000-06-01)

Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease
by: Shaila P. Handattu, et al.
Published: (2009-06-01)

Role of Short Chain Fatty Acids and Apolipoproteins in the Regulation of Eosinophilia-Associated Diseases
by: Eva Maria Sturm, et al.
Published: (2021-04-01)

Phospholipid transfer protein (PLTP) causes proteolytic cleavage of apolipoprotein A-I
by: M. Jauhiainen, et al.
Published: (1999-04-01)

Lower HDL-C and apolipoprotein A-I are related to higher glomerular filtration rate in subjects without kidney disease[S]
by: Jan A. Krikken, et al.
Published: (2010-07-01)

Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally[S]
by: Mohamad Navab, et al.
Published: (2011-06-01)

Significance of determining levels of apolipoproteins A-I and B in the diagnostics and assessment of lipid-related atherogenic risk in hyperalpha-lipoproteinemia, hypocholesterolemia and hypo-HDL-chol
by: Kojić-Damjanov Sunčica, et al.
Published: (2007-01-01)

Relationship between Apolipoprotein Superfamily and Parkinson's Disease
by: Lin Li, et al.
Published: (2017-01-01)

Apolipoprotein B/A1 Ratio as a Diagnostic Alternative to Triglycerides and HDL-Cholesterol for the Prediction of Metabolic Syndrome among Hypertensives in Kazakhstan
by: Alma Nurtazina, et al.
Published: (2020-07-01)

Peptide model of a highly conserved, N-terminal domain of apolipoprotein E is able to modulate lipoprotein binding to a member of the class A scavenger receptor family
by: Samuel R. Dominguez, et al.
Published: (1999-04-01)

Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis
by: Mohamad Navab, et al.
Published: (2015-04-01)

Characterization and quantification of serum lipoprotein subfractions by capillary isotachophoresis: relationships with lipid, apolipoprotein, and lipoprotein levels
by: Alexandra Schlenck, et al.
Published: (1999-11-01)

Apolipoprotein M
by: Nilsson-Ehle Peter, et al.
Published: (2004-10-01)

Apolipoprotein E and its mimetic peptide suppress Th1 and Th17 responses in experimental autoimmune encephalomyelitis
by: Junjie Wei, et al.
Published: (2013-08-01)